If the solution is cloudy or contains particulates, the peptide may not have dissolved properly or, in rare cases, could indicate a problem with the product
You should seek medical advice promptly if you: Are currently prescribed testosterone and are considering joining a retatrutide clinical trial Have noticed symptoms of hormonal imbalance such as fatigue, mood changes, reduced libido, or unexpected weight changes while on either treatment Have a history of polycythaemia, liver disease, prostate conditions, or cardiovascular disease, as these may affect suitability for either treatment Are sourcing retatrutide from unregulated online suppliers, which carries serious risks of counterfeit or contaminated products Seek urgent medical attention call 999 or use NHS 111 if you experience: Chest pain, palpitations, or breathlessness Severe, persistent upper abdominal pain (particularly if it radiates to the back), vomiting, or jaundice, which may indicate pancreatitis or gallbladder disease For those already on testosterone therapy through the NHS or a regulated private provider, it is important to inform your prescribing clinician of any new treatments including investigational drugs so that monitoring plans can be adjusted accordingly
Akamizu T, Takaya K, Irako T, et al
While clinical trials show an average weight loss of 10.2%, in reality, some people lose over 25% of their body weight, while 32.2% lose less than 5% or even gain weight
some plans exclude anti-obesity medications entirely
